Stockscreener 앱 받기
2.0003
2.30%
0.0403
전일 마감가:
$1.96
열려 있는:
$1.935
하루 거래량:
1.15M
Relative Volume:
0.46
시가총액:
$455.90M
수익:
-
순이익/손실:
$-179.82M
주가수익비율:
-1.504
EPS:
-1.33
순현금흐름:
$-159.16M
1주 성능:
+15.56%
1개월 성능:
+17.94%
6개월 성능:
+45.29%
1년 성능:
+135.94%
1일 변동 폭
$1.92
$2.0298
1주일 범위
$1.745
$2.0298
52주 변동 폭
$0.6617
$2.23
Gossamer Bio Inc Stock (GOSS) Company Profile
명칭
Gossamer Bio Inc
전화
(858) 684-1300
주소
3115 MERRYFIELD ROW, SAN DIEGO, CA
GOSS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
2.005 | 445.67M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.98 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.85 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.16 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
323.92 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-05 | 재개 | Wedbush | Outperform |
| 2023-07-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-03-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 개시 | Guggenheim | Neutral |
| 2022-12-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-07 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | JP Morgan | Neutral |
| 2022-09-19 | 개시 | Wedbush | Outperform |
| 2022-04-18 | 개시 | Raymond James | Outperform |
| 2022-04-06 | 개시 | UBS | Buy |
| 2022-01-10 | 업그레이드 | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 재개 | Piper Sandler | Overweight |
| 2020-06-29 | 개시 | H.C. Wainwright | Buy |
| 2020-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-30 | 개시 | Berenberg | Buy |
| 2019-03-05 | 개시 | Barclays | Overweight |
| 2019-03-05 | 개시 | BofA/Merrill | Buy |
| 2019-03-05 | 개시 | Evercore ISI | Outperform |
| 2019-03-05 | 개시 | SVB Leerink | Outperform |
모두보기
Gossamer Bio Inc 주식(GOSS)의 최신 뉴스
Will Gossamer Bio Inc. continue its uptrendGold Moves & Smart Swing Trading Techniques - Newser
Automated trading signals detected on Gossamer Bio Inc.2025 Stock Rankings & Real-Time Chart Breakout Alerts - Newser
What machine learning models say about Gossamer Bio Inc.Portfolio Return Report & AI Enhanced Execution Alerts - Newser
Chartists Watching For Breakout in Gossamer Bio Inc.2025 Key Lessons & Fast Gain Swing Alerts - beatles.ru
Why Gossamer Bio Inc. is moving todayJuly 2025 Intraday Action & Daily Chart Pattern Signals - Newser
What institutional flow reveals about Gossamer Bio Inc.Weekly Trade Summary & Accurate Entry and Exit Point Alerts - Newser
Multi asset correlation models including Gossamer Bio Inc.Weekly Stock Report & Safe Capital Growth Trade Ideas - Newser
What is the earnings history of Gossamer Bio Inc.Global Markets & Fast Gaining Stock Reports - classian.co.kr
Gossamer Bio Revenue Estimates Surge Higher Amid Analyst Upgrades - AInvest
Analysts' Revenue Estimates For Gossamer Bio, Inc. (NASDAQ:GOSS) Are Surging Higher - Yahoo Finance
Pulmonary Hypertension associated with Interstitial Lung Disease Market to Witness Upsurge in Growth During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Gossamer Bio shares rise 1.52% after-hours following XOMA Royalty's acquisitions and pipeline advancements. - AInvest
Gossamer Bio Reports Q2 2025 Financial Results - TipRanks
Analyzing recovery setups for Gossamer Bio Inc. investorsAI-Powered Stock Trend Movement Analysis - Newser
Q3 EPS Estimates for Gossamer Bio Increased by HC Wainwright - Defense World
Wedbush Has Optimistic Outlook of Gossamer Bio Q3 Earnings - Defense World
Will Gossamer Bio Inc. see short term momentumStock Portfolio Risk and Return Analysis - Newser
Is Gossamer Bio Inc. stock poised for growthGrowth Watchlist for Long Term Positioning - Newser
Institutional investors in Gossamer Bio, Inc. (NASDAQ:GOSS) see US$54m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Is Gossamer Bio Inc. trending in predictive chart modelsOversold Stock Bounce Playbook Generator - Newser
What makes Gossamer Bio Inc. stock price move sharplyReal-Time Investment Signal Forecast with AI - Newser
Gossamer Bio (NASDAQ:GOSS) Stock Rating Lowered by Wall Street Zen - Defense World
Real time scanner hits for Gossamer Bio Inc. explainedMarket Timing Strategy with Technical Filters - Newser
Q3 EPS Estimates for Gossamer Bio Lowered by Leerink Partnrs - Defense World
H.C. Wainwright Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 7, 2025 - BioSpace
Gossamer Bio earnings beat by $0.01, revenue topped estimates - Investing.com Australia
Gossamer Bio Reports Q2 2025 Financials, Announces PROSERA Phase 3 Topline Results Expected in February 2026, and First Site Activations for Registrational Phase 3 SERANATA Study in PH-ILD Expected in Q4 2025. - AInvest
Gossamer Bio 2025 Q2 Earnings Sharp Net Loss Amid Revenue Drop - AInvest
Gossamer Bio 2025 Q2 Earnings Sharp Net Income Decline of 177.7% - AInvest
Gossamer Bio shares fall 7.41% premarket despite beating earnings expectations. - AInvest
Gossamer Bio Inc. Exceeds Q2 Expectations Despite LossNews and Statistics - IndexBox
Gossamer Bio: Q2 Earnings Snapshot - New Haven Register
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
How Gossamer Bio Inc. stock performs during market volatilityBuy and Exit Strategy Based on Momentum - Newser
Gossamer Bio shares rise 1.39% after-hours despite Q2 revenue drop of 88%. - AInvest
GOSS Achieves Strong Q2 Revenue and Prepares for Commercial Expa - GuruFocus
Gossamer Bio Reports Q2 Revenue Drop of 88% - AInvest
Gossamer Bio Q2 revenue drops 88% - MarketScreener
Gossamer Bio's 390-Patient PAH Trial Nears Crucial February Readout, $213M Cash Runway - Stock Titan
Will Gossamer Bio Inc. price bounce be sustainableFree Smart Trade Plans With Risk Protection - Newser
Can Gossamer Bio Inc. rally from current levelsStrategy Builder for Growth Focused Traders - Newser
Why is Gossamer Bio Inc. stock attracting strong analyst attentionExponentially increasing returns - Jammu Links News
Custom strategy builders for tracking Gossamer Bio Inc.Market Liquidity and Price Flow Analysis - Newser
Published on: 2025-08-04 06:30:01 - beatles.ru
Is Gossamer Bio Inc. forming a reversal patternReal-Time Investment Signal Forecast with AI - Newser
How volatile is Gossamer Bio Inc. stock compared to the marketCapitalize on market momentum for maximum gains - Jammu Links News
Why Gossamer Bio Inc. stock attracts strong analyst attentionLong-Term Allocation Strategy Summary Breakdown - Newser
What are the latest earnings results for Gossamer Bio Inc.Capitalize on fast-moving stock trends - Jammu Links News
What is the dividend policy of Gossamer Bio Inc. stockCapitalize on high-yield stocks early - Jammu Links News
Gossamer Bio Inc (GOSS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.30%
자본화:
|
볼륨(24시간):